Version 1
: Received: 1 June 2021 / Approved: 2 June 2021 / Online: 2 June 2021 (10:06:30 CEST)
How to cite:
Huang, X.; Li, X.; Luo, L. Chemotherapy-Induced Nausea and Vomiting Breast Cancer Patients from a Chinese Multicenter Prospective Longitudinal Observational Study. Preprints2021, 2021060064. https://doi.org/10.20944/preprints202106.0064.v1
Huang, X.; Li, X.; Luo, L. Chemotherapy-Induced Nausea and Vomiting Breast Cancer Patients from a Chinese Multicenter Prospective Longitudinal Observational Study. Preprints 2021, 2021060064. https://doi.org/10.20944/preprints202106.0064.v1
Huang, X.; Li, X.; Luo, L. Chemotherapy-Induced Nausea and Vomiting Breast Cancer Patients from a Chinese Multicenter Prospective Longitudinal Observational Study. Preprints2021, 2021060064. https://doi.org/10.20944/preprints202106.0064.v1
APA Style
Huang, X., Li, X., & Luo, L. (2021). Chemotherapy-Induced Nausea and Vomiting Breast Cancer Patients from a Chinese Multicenter Prospective Longitudinal Observational Study. Preprints. https://doi.org/10.20944/preprints202106.0064.v1
Chicago/Turabian Style
Huang, X., Xu-Ying Li and Lu Luo. 2021 "Chemotherapy-Induced Nausea and Vomiting Breast Cancer Patients from a Chinese Multicenter Prospective Longitudinal Observational Study" Preprints. https://doi.org/10.20944/preprints202106.0064.v1
Abstract
Aims: To assess the occurrence of Chemotherapy-induced nausea and vomiting (CINV) after standard antiemetic therapy in the acute (24 h post-chemotherapy) and delayed (2–5 days post-chemotherapy) phases, as well as to identify risk factors for CINV in the acute and delayed phases. Methods: This prospective longitudinal and observational study analyzed the data of 400 breast cancer patients scheduled for chemotherapy over two cycles in two hospitals. The self-report survey was developed to assess the occurrence of CINV and their associated factors. CINV was evaluated with a Multinational Association of Supportive Care in Cancer Antiemetic Tool (MAT) on days 2 and 6 of chemotherapy. The incidence of acute and delayed CINV were presented by frequency and percentage. Generalized equation estimates (GEE) was used to identify risk factors of acute and delayed CINV. Results: There were 400 evaluable patients with complete Round 1 data, 334 for Round 2 data. Among 400 patients, 29.8% and 23.5% experienced acute and delayed CINV, respectively. Risk factors associated with for acute CINV were pain/insomnia, history of CINV, history of motion sickness (MS), and highly emetogenic chemotherapy regimen, while history of MS, CINV history, number of completed chemotherapy cycle number < 3, and the incidence of acute CINV were risk factors of delayed CINV (all p < 0.05). Conclusions: The findings may help nurses working for Chinese population in identifying patients at risk for CINV and in planning effective program to reduce the occurrence of CINV.
Keywords
CINV; breast cancer; antiemetic guidelines; risk factors
Subject
Medicine and Pharmacology, Immunology and Allergy
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
